Substaging pathologically organ confined (pT2) prostate cancer: An exercise in futility?

European Urology

Volumn 49, Issue 2, 2006, Pages 209-211

  Van Der Kwast, Th H ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; COHORT ANALYSIS; EDITORIAL; FOLLOW UP; GLEASON SCORE; HUMAN; HYPERPLASIA; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER;

DIGITAL RECTAL EXAMINATION; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 32044437616     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.12.027     Document Type: Editorial

References (11)

1. D.G. Bostwick Staging prostate cancer - 1987: Current methods and limitations Eur Urol 32 S3 1997 2 14
2. F.K.H. Chun, A. Briganti, T. Lebeau, V. Fradet, T. Steuber, and J. Walz The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy Eur Urology 49 2006 273 279
3. F. May, R. Hartung, and J. Breul The ability of the American joint committee on cancer staging system to predict progression-free survival after radical prostatectomy BJU International 88 2001 702 707
4. S.J. Freedland, A.W. Partin, J.I. Epstein, and P.C. Walsh Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b Cancer 100 2004 1646 1649
5. R.F. Hoedemaker, J.B.W. Rietbergen, R. Kranse, T.H. van der Kwast, and F.H. Schröder Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer World J Urol 15 1998 339 345
6. C.G. Ramos, G.F. Carvalhal, D.S. Smith, D.E. Mager, and W.J. Catalona Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a prostate cancer J Urol 161 1999 1525 1529
7. S.A. Armatys, M.O. Koch, R. Bihrle, T.A. Gardner, and L. Cheng Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma? BJU International 96 2005 777 780
8. S.J. Freedland, J.C. Presti, M.K. Terris, C.J. Kane, W.J. Aronson, and F. Dorey Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: Results from the search database J Urol 169 2003 2129 2135
9. I. Cagiannos, M. Graefen, P.I. Karakiewicz, M. Ohori, J.A. Eastham, and F. Rabbani Analysis of clinical stage T2 prostate cancer: Do current subclassifications represent an improvement? J Clin Oncol 20 2002 2025 2030
10. L.E. Eichelberger, and L. Cheng Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma Cancer 100 2004 2573 2576
11. A.M. Wise, T.A. Stamey, J.E. McNeal, and J.L. Clayton Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens Urology 60 2002 264 269